GSK-2593074A)

Request For Quotation
GSK-2593074A) Suppliers list
Company Name: BOC Sciences  
Tel: 1-631-485-4226; 16314854226
Email: info@bocsci.com
Company Name: Shanghai YuanYe Biotechnology Co., Ltd.  
Tel: 15026964105
Email: 2881489226@qq.com
Company Name: Fan De(Beijing) Biotechnology Co., Ltd.  
Tel: 15911056312
Email: liming@bio-fount.com
Company Name: TargetMol Chemicals Inc.  
Tel: +1-781-999-5354; +1-00000000000
Email: marketing@targetmol.com
Company Name: InvivoChem  
Tel: +1-708-310-1919 +1-13798911105
Email: sales@invivochem.cn

GSK-2593074A) manufacturers

  • GSK2593074A
  • GSK2593074A pictures
  • $116.00
  • 2026-07-27
  • CAS:1337531-06-2
  • Purity: 99.99%
  • Supply Ability: 10g
  • GSK2593074A
  • GSK2593074A pictures
  • $116.00
  • 2026-07-27
  • CAS:1337531-06-2
  • Purity: 99.99%
  • Supply Ability: 10g
GSK-2593074A) Basic information
Product Name:GSK-2593074A)
Synonyms:GSK2593074A (GSK'074;GSK-2593074A);GSK'074;Ethanone, 1-[5-[4-amino-7-(1-methyl-1H-pyrazol-4-yl)thieno[3,2-c]pyridin-3-yl]-2,3-dihydro-1H-indol-1-yl]-2-phenyl-;GSK2593074A,GSK-2593074A;GSK2593074A, 10 mM in DMSO
CAS:1337531-06-2
MF:C27H23N5OS
MW:465.57
EINECS:
Product Categories:
Mol File:1337531-06-2.mol
GSK-2593074A) Structure
GSK-2593074A) Chemical Properties
Boiling point 807.6±65.0 °C(Predicted)
density 1.39±0.1 g/cm3(Predicted)
storage temp. Store at -20°C
solubility DMSO : 41.67 mg/mL (89.50 mM; Need ultrasonic)
form Solid
pka5.79±0.40(Predicted)
color Light yellow to khaki
Safety Information
MSDS Information
GSK-2593074A) Usage And Synthesis
UsesGSK2593074A (GSK’074) is a necroptosis inhibitor with dual targeting ability to both RIP1 and RIP3[1].
in vivo

GSK2593074A (GSK’074; 0.93 mg/kg/day; i.p. injection; 14 or 28 days) is administrated to Apoe-/- mice immediately following pump implantation. Compared to the DMSO group, GSK2593074A-treated mice show significantly alleviated aneurysm formation, reflected by a much smaller aortic dilatation (DMSO 85.39±15.76% vs GSK2593074A 36.28±5.76%; P<0.05) as well as a reduced abdominal aortic aneurysm (AAA) incidence (from 83.3 to 16.7%). GSK2593074A significantly decreases the extent of aortic expansion (DMSO 66.06±9.17% vs GSK2593074A 27.36±8.25%; P<0.05) [1].

Animal Model:Apoe-/- female mice (9-10 months)[1]
Dosage:0.93mg/kg/day; 200μL
Administration:Daily i.p. injection; 14 or 28 days
Result:Inhibited aneurysm formation in mouse models of aneurysms.
References[1] Zhou T, et al. Identification of a novel class of RIP1/RIP3 dual inhibitors that impede cell death and inflammation in mouse abdominal aortic aneurysm models. Cell Death Dis. 2019 Mar 6;10(3):226. DOI:10.1038/s41419-019-1468-6
GSK-2593074A) Preparation Products And Raw materials
Tag:GSK-2593074A)(1337531-06-2) Related Product Information
GSK-2593074A) 5-Pyrimidinecarboxamide, 2-[(3S)-3-amino-1-piperidinyl]-4-[[2,6-bis(1-methylethyl)-4-pyridinyl]amino]- 1,6-Naphthyridin-2(1H)-one, 3-(3-hydroxyphenyl)-1-methyl-7-[[3-(4-methyl-1-piperazinyl)phenyl]amino] NA GSK872 ponicidin